Gardasil News and Research

RSS

Gardasil is a vaccine that prevents the types of genital human papillomavirus (HPV) that cause most cases of cervical cancer and genital warts. The vaccine, Gardasil, is given in three shots over six-months. The vaccine is routinely recommended for 11 and 12 year old girls. It is also recommended for girls and women age 13 through 26 who have not yet been vaccinated or completed the vaccine series.

Single dose of Cervarix vaccine effective in preventing HPV infections

A single dose of the human papillomavirus (HPV) vaccine Cervarix appears to be as effective in preventing certain HPV infections as three doses, the currently recommended course of vaccination.

10 Jun 2015

9-Valent HPV vaccine can potentially prevent 80% of cervical cancers in the U.S.

The new 9-valent human papillomavirus vaccine, can potentially prevent 80 percent of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus.

12 May 2015

Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Merck, known as MSD outside the United States and Canada, announced today that GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck's 9-valent human papillomavirus (HPV) vaccine, is now available in Canada.

1 Apr 2015

Duke study proposes strategy to protect more people from HPV using limited public funds

A Duke University study proposes a strategy to better use limited public health care dollars for protecting more people from a sexually transmitted infection called human papillomavirus (HPV) and the cancers it can cause.

12 Mar 2015

International phase 2/3 trial shows Gardasil 9 vaccine protects against nine HPV types

Approximately 12,000 women are diagnosed with cervical cancer each year in the United States and another 4,000 die annually from the disease. However, most cervical cancers are preventable through immunization against the human papillomavirus (HPV). A pivotal international phase 2/3 clinical trial involving Moffitt Cancer Center faculty demonstrated that vaccination with Gardasil 9 protects against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease.

21 Feb 2015

New nine-valent HPV vaccine has potential to dramatically reduce cervical cancer rates

A multinational study on a diverse group of women shows that a new nine-valent human papillomavirus (HPV) vaccine prevents infections and disease associated with the vaccine types, according to a paper published today in The New England Journal of Medicine.

19 Feb 2015

HPV vaccine does not increase rates of STIs in adolescent females

Receiving the human papillomavirus vaccine does not increase rates of sexually transmitted infections (STIs) in adolescent females. The vaccine, which can prevent cervical cancer in women, has had a low uptake, partly because of concerns about how it will affect adolescent sexual activity.

10 Feb 2015

MD Anderson president applauds FDA's approval of new vaccine for HPV-related cancers

The Food and Drug Administration's approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center.

12 Dec 2014

Study correlates HPV vaccine series completion among young US women

According to a recent study in the journal Human Vaccines & Immunotherapeutics, only 60% of young US women who received the first dose of the human papilloma virus (HPV) vaccine went on to complete the three-dose vaccine series.

29 Sep 2014

Study shows sustained immunogenicity, efficacy and safety of GlaxoSmithKline's HPV vaccine

A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix.

1 Aug 2014

Survey shows biggest barrier to receiving Human Papillomavirus vaccine

A survey of first-year Grand Valley State University students showed the biggest barrier to receiving a Human Papillomavirus (HPV) vaccine was moral or religious beliefs, or a perceived promotion of sexual behavior, according to graduate physician assistant researchers.

8 Jul 2014

Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer's recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds.

12 May 2014

Study: HIV-positive women respond well to vaccine against human papillomavirus

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial.

17 Apr 2014

Adverse events linked with HPV vaccine appear to be related with media coverage

The number of adverse events associated with the HPV vaccine reported to the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) appeared to be related to media coverage and online controversy about the vaccine, finds a study in the Journal of Adolescent Health.

20 Nov 2013

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

Women vaccinated with one dose of a human papillomavirus (HPV) vaccine had antibodies against the viruses that remained stable in their blood for four years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses and protection against new HPV infections, and ultimately cervical cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

4 Nov 2013

Parental perceptions pose major barrier to acceptance of HPV vaccination

A Mayo Clinic physician and two other pediatric experts say that parental perceptions pose a major barrier to acceptance of human papillomavirus (HPV) vaccination — and that many of those perceptions are wrong.

22 Oct 2013

New article in Preventive Medicine journal explores suspicions about sexual promiscuity, vaccine safety

Suspicions about sexual promiscuity and vaccine safety are explored in an article in the November issue of the journal Preventive Medicine, which dedicates a section of that issue to research concerning the human papillomavirus.

18 Oct 2013

Researchers find no serious adverse effects of HPV vaccine in girls

Researchers at Karolinska Institutet in Sweden and their Danish colleagues have monitored HPV-vaccinated girls via patient data registries in order to examine the incidence of a wide range of diseases and thus determine if there are any serious adverse effects of the vaccine. Their results show no significant increase of the examined diseases in the vaccinated girls relative to their unvaccinated peers.

10 Oct 2013

Emphasizing STD prevention will persuade young women to get HPV vaccine, study suggests

The HPV vaccine can prevent both cervical cancer and a nasty sexually transmitted disease in women.

3 May 2013

Research: HIV women infected with HPV are not protected by current vaccines

Women with HIV acquire cancer-causing forms of the human papillomavirus (HPV) that are not included in the current HPV vaccines Gardasil and Cervarix, according to new research from Fox Chase Cancer Center being presented at the AACR Annual Meeting 2013 on Sunday, April 7.

8 Apr 2013